Revision of bluebird bio

{{DISPLAYTITLE:Bluebird bio}}
bluebird bio, Inc., based in Cambridge, Massachusetts, is a biotechnology company that develops gene therapies for severe genetic disorders and cancer.The company's only - in the European Union (EU) - approved drug is betibeglogene autotemcel (Zynteglo), which treats transfusion-dependent beta thalassemia (TDT), a rare genetic blood disorder, and has been approved for use by the European Medicines Agency.<small> from [https://en.wikipedia.org/wiki/Bluebird_bio Wikipedia]</small>
{|
|+ 
|-
! Icon !! Service !! Username !!
|-
| [[File:TwitterGrey.svg|30px|link=|frameless|center]] || Twitter || [https://www.twitter.com/bluebirdbio @bluebirdbio] || [[File:OOjs UI icon check-progressive.svg|30px|link=|frameless|center]]
|-
| [[File:WebsiteGrey.png|29px|link=|frameless|center]] || Website || [https://www.bluebirdbio.com/ https:www.bluebirdbio.com] || [[File:OOjs UI icon check-progressive.svg|30px|link=|frameless|center]]
|-
| [[File:InstagramGrey.svg|30px|link=|frameless|center]] || Instagram || [https://www.instagram.com/bluebird_bio @bluebird_bio] || [[File:OOjs UI icon check-progressive.svg|30px|link=|frameless|center]]
|}

[[VHID]]:[https://verifiedhandles.com/vhid/56205826167 56205826167]
{{#subtitle: <big>American pharmaceutical company</big>}}